High-throughput screening (HTS) efforts to discover "hits" typically rely on the large-scale parallel screening of individual compounds with attempts to screen mixtures of compounds typically and, unfortunately, giving rise to false positives and false negatives due to the nature of the HTS readout (% inhibition/activation above a defined threshold) that makes deconvolution virtually intractable. Bioaffinity screening methods have emerged as an alternative or orthogonal method to classic HTS. One of these methods, frontal affinity chromatography coupled to mass spectrometry detection (FAC-MS), although still a relatively new technique, is turning out to be a viable screening tool. However, to push FAC-MS more to the forefront as a moderate primary HTS system (or a secondary screening assay), automation needs to be addressed. An automated FAC-MS system is described using 2 columns containing immobilized hERβ, whereby while 1 column is being regenerated, the other is being used. The authors are extrapolating that in a continuous 24-h operation, the number of ligands screened could potentially approach 10,000. In addition, preliminary structure-activity relationship binding information (typically not seen in early primary HTS) can be obtained by observing the rank order of the library members in the various mixtures. (Journal of Biomolecular Screening 2007:167-174) 
INTRODUCTION
H IGH-THROUGHPUT SCREENING (HTS) is the main paradigm of the drug discovery process today; over time, miniaturization and throughput have increased, 1 but it can be argued that HTS has not fully delivered on its promise. Moreover, HTS datarelated challenges include high false-positive and false-negative rates, the requirement for reporter assays, and the limitation of only being able to screen compounds individually. 2 Consequently, eliminating the requirement for functional reporter assays and developing the ability to monitor multiple compounds simultaneously in an HTS assay format would certainly be beneficial.
Bioaffinity screening methods have emerged as an alternative or orthogonal method to classic primary HTS screening for early hit discovery. These methods rely on binding event readouts as opposed to functional event readouts. A number of techniques (albeit limited) have shown utility in screening compound mixtures but arguably only at a moderate throughput. Those requiring the physical separation of the protein target-ligand(s) complex and a subsequent deconvolution step include the automated ligand identification system (ALIS), 3 affinity capillary electrophoresis coupled to mass spectroscopy (ACE-MS), 4 Speedscreen, 5 and pulsed ultracentrifugation-mass spectroscopy (PUF-MS). 6 Techniques not requiring the separation of the protein target-ligand(s) complex include bioaffinity characterization mass spectroscopy (BAC/MS), 7 affinity nuclear magnetic resonance (NMR), 8 centrifugally driven affinity selection (SpinScreen), 9 and frontal affinity chromatography coupled to mass spectrometry detection (FAC-MS). 10, 11 FAC-MS has the added advantage that it can rank order the bound ligands (although Spinscreen potentially can crudely rank order ligands as well).
FAC-MS, although still a relatively new technique, is turning out to be a viable screening tool that has been successfully applied to a wide range of biological targets. [11] [12] [13] Moreover, FAC-MS has the ability to identify individual m/z values for ligands and certainly has the capability to assay mixtures. In fact, as noted above, FAC-MS has been used successfully to screen ligand mixtures against a variety of immobilized targets. However, to push FAC-MS more to the forefront as a moderate primary HTS system (as well as a secondary screening assay), automation needs to be addressed.
Basically, FAC-MS takes advantage of the ongoing equilibrium between binding ligands flowing through a column containing an immobilized protein target. As ligands flow through the column and interact (bind) with the target, individual ligands are retained in the column by their interaction with the protein target. This causes an increase in each ligand's specific "breakthrough volume," which is the effluent volume passing through the column that allows the output ligand concentration to equal the input ligand concentration. The breakthrough volume, characterized as a sigmoidal front, can readily be detected by mass spectrometry based on the ligand's m/z value and corresponds directly to the time that the front is observed to pass through the column. Hence, tighter binding compounds elute later, whereas compounds that do not interact with the target elute with the void volume of the column. The order of compounds eluting parallels their affinity, meaning that FAC-MS offers a convenient method for measuring and ranking the relative binding affinities of ligands in a mixture against an immobilized protein target. FAC-MS can also be used in a more rigorous mode for determining thermodynamic binding constants, K d , of individual compounds.
At the early hit discovery stage in the drug discovery process, FAC-MS can be used in 2 ways, in either "indicator" or "Q1 scan" modes. The indicator method, which is well documented, determines the extent (or percentage) to which a ligand(s) shifts an indicator (a ligand with a known affinity to a known binding site) for a particular target. 13 With this method, the FAC-MS readout (percentage shift of the indicator) can be used to rank the binding of ligands or ligand mixtures-that is, the greater the percentage shifts, the greater the degree of competition for the indicator. As shown pictorially in Figure 1 , the percentage shift of the indicator is determined from the following equation:
where t is the breakthrough time difference, measured at the inflection point, of the sigmoidal fronts between the indicator and void marker (a ligand that does not interact with the target and gives the void volume of the column) in the presence of any competing ligand(s); t NSB is the nonspecific binding breakthrough time difference in the absence of immobilized protein (and is a constant for the indicator used); and t I is the breakthrough time difference in the absence of any competing ligands. In this manner, the FAC-MS percentage shifts can be used to rank the binding affinity of ligands and only those mixtures in which a significant displacement (or shift) of the indicator merits further investigation and requires deconvolution. Moreover, we have recently demonstrated that the relative displacement of an "indicator" molecule binding at a specific binding site of an immobilized protein target by an individual member of a compound mixture correlates well with both the K d and the IC 50 value of the individual compound. 13 The Q1 scan FAC-MS screening method, in which multiple ligands are analyzed simultaneously, has not been described in detail and is the focus of this report.
MATERIALS AND METHODS

Materials
Controlled Pore Glass (CPG) beads, type CBX1000C, were obtained from Millipore (Bedford, MA). Mannotriose (M3, αMan(1→3)[αMan(1→6)]βManO-octyl) was obtained from Calbiochem (San Diego, CA). Norethindrone, estradiol, EDC, NHS, and bovine serum albumin (BSA) were obtained from Sigma (Oakville, Ontario, Canada). The ligand binding domain of human estrogen receptor β (hERβ), expressed as a 21-amino acid tagged sequence containing 6 histine residues, with 3 cystines mutated to serine that had been shown to stabilize ERβ as reported in the literature, 14 was obtained from TopGene (Montreal, Canada). The small molecule library was obtained from ChemDiv (San Diego, CA).
FAC-MS hERβ β immobilization
The CPG CBX1000C beads (10 mg) were suspended in 900 µL activation buffer (0.1 M MES, 0.5 M NaCl [pH 6.4]). To the suspension was added 50 µL freshly prepared EDC (100 mg/mL) and 50 µL NHS (200 mg/mL), and the mixture was incubated for 45 min at room temperature with 360°vertical rotation to keep beads in suspension. The suspension was centrifuged and the supernatant removed, and the beads were resuspended in activation buffer containing hERβ (200 µg), incubated at room temperature for 2 h with 360°vertical rotation, and then incubated overnight at 4 o C. BSA (10 µL, 100 mg/mL) was added and the beads stored at 4 o C. After loading the immobilized protein, the FAC-MS capillary columns (250 µm id × 2.5 cm) were washed with 50 µL at a flow rate of 200 µL/h of phosphate-buffered saline (PBS) followed by 50 µL of the running buffer (12.5 mM NH 4 HCO 3 containing 1% DMSO). Analyte solutions were prepared to contain the indicator norethindrone (1 µM), M3 (1 µM), and a single ligand (5 µM) in 12.5 mM NH 4 HCO 3 containing 1% DMSO. For the case of multiple ligand mixtures, in addition to norethindrone (1 µM) and M3 (1 µM), each ligand was prepared in the mixture at either a concentration of 1 µM (100 compounds) or 0.5 µM (200 compounds) in 12.5 mM NH 4 HCO 3 containing 2% DMSO. The makeup buffer was 90% methanol containing 0.1% acetic acid in water. The flow rates used were 800 µL/h for the makeup buffer and 100 µL/h for the FAC-MS columns.
FAC-MS system and automation
The API 3000 triple-quadrupole mass spectrometer (MS) equipped with an ESI interface was obtained from Applied Biosystems/Sciex (Concord, Ontario, Canada). Syringe pumps (PicoPlus) were obtained from Harvard Biosciences (Holliston, MA). The micropumps (HP 1100 series) were obtained from Agilent (Mississauga, Ontario, Canada), and the autosampler (Famos) and column switcher (Switchos) were obtained from LC Packings (Sunnyvale, CA). The FAC-MS capillary columns loaded with protein beads were held in modified a custom column holder obtained from Upstate (Oak Harbour, WA) with frits included to hold the beads in place.
The general setup of the FAC-MS hardware has been described before, 13 but to automate the system, the autosampler and column switcher were placed between an HPLC micropump containing the running buffer and the MS. An additional HPLC micropump was used to deliver the makeup buffer to the MS. These micropumps serve 2 purposes: first, syringe pumps do not have the capacity to run overnight unattended, and second, the micropump delivers the makeup buffer at a consistent steady rate that markedly improves the MS signal-to-noise ratio. The micropump containing the running buffer is connected in series to the autosampler and then to the column switcher equipped with 1 or 2 columns (3 columns are also possible with an additional column switcher) and then connected to the MS. A syringe pump is connected to the column switcher to wash one column while the other is being used. The makeup buffer is then teed into the system postcolumn (see Fig. 2 ). Typically, in the automated mode, the selected column with immobilized protein is washed with the running buffer for a preselected period of time for automated injections. The data are analyzed using proprietary software to determine the breakthrough times of the void marker, M3, and the various ligands.
RESULTS AND DISCUSSION
To illustrate FAC-MS automation, we chose to use the ligand binding domain of hERβ for several reasons. It was expressed as a 21-amino acid tagged sequence containing 6 histine residues with 3 cystines mutated to serine that had been shown to stabilize hERβ but did not affect the ligand binding activity. 14 Also, this hERβ has been used successfully in a previous FAC-MS study, although immobilized to beads in a different fashion. 12 Finally, we had prior knowledge that our covalently immobilized hERβ beads were very stable and contained a significant amount of immobilized protein.
For these FAC-MS experiments, hERβ was immobilized to controlled pore glass (CPG) beads containing free carboxyl groups (CBX1000C) by covalent attachment using EDC and NHS. Previously, this same hERβ was used in FAC-MS studies, but it was first biotinylated and then immobilized to streptavidincoated CPG beads. 12 To determine whether the hERβ FAC-MS columns contained active protein, norethindrone (K i = 1.064 µM) 12 was infused at a concentration of 1 µM. As shown in Figure 3 , the norethindrone (thick line) breakthrough time was 21.5 min, 13.5 min longer than the void marker (thin line), mannotriose, M3. Because the nonspecific binding breakthrough time of norethindrone to the FAC-MS system (capillary lines, beads, etc.) in the absence of hERβ was only 2 min (data not shown), the resulting net binding time of 11.5 min over the void marker confirmed binding activity. Interestingly, using this direct method of immobilization for this hERβ, an enhanced binding time for norethindrone was seen compared to the biotinylation/streptavidin attachment carried out previously, presumably because an increased density of protein was attached to the beads. During a FAC-MS screening run, ligands are being continuously infused. Depending on how ligands are selected, it is possible that in an infusion, there may be a set of ligands that possesses a range of affinities for the immobilized protein target. As ligands flow through the column, individual ligands are retained in the column based on their affinity. Tighter binding compounds elute later, whereas compounds that do not interact with the target elute with the void volume of the column. The order of compounds eluting parallels their affinity, meaning that FAC-MS offers a convenient method for measuring and ranking the relative binding affinities of mixtures of ligands.
An additional phenomenon can also occur with the continuous infusion of ligands. Weaker ligands pass through the column, propagating at a higher linear velocity (because they are not retained as tightly) than more potent ligands. Over time, as the column equilibrates with the more potent ligands, the weaker ligands get displaced, add to their infusion concentrations, and generate a transient over concentration (or rollup) of the weaker ligands that appear as peak-like shapes in the FAC-MS chromatograms. Although rollups were seen previously for hERβ (although immobilized through the biotinylation/streptavidincoated CPG beads complex), we show in Figure 4 a very clear example of a rollup of norethindrone (thick line) caused by estradiol (not monitored) using hERβ covalently attached to the CBX beads. The rollup of norethindrone is clearly evident because its ion intensity as its front elutes initially is much greater than when equilibrium is established, and its infusion concentration equals its concentration eluting from the column. The 1230-fold difference in the binding affinities of norethindrone (FAC-MSmeasured K d = 1.6 µM) and estradiol (FAC-MS-measured K d = 1.3 nM) 12 for this hERβ, as well as the fact that we used a 5-fold excess in the concentration of estradiol (5 µM) versus norethindrone (1 µM), accounts for this rollup.
For the typical HTS screen designed to discover "hits," the data generated are usually a yes or no based on a percent inhibition/activation threshold level being reached, but at this point it is not possible to rank the hits. It is only after the hits are validated with IC 50 values or some other activity measurement in a secondary assay that the hits can be rank ordered, giving rise to preliminary structure-activity relationships (SAR). Although typically, the use of SAR is reserved for a comprehensive collection of ligands belonging to the same chemical series, it would be very useful, at the hit discovery stage, to know which scaffolds are more potent than others.
The FAC-MS screening system suggests that "preliminary binding SAR" information can be garnered when screening multiple ligands with diverse scaffolds (and also with a focused library) at the hit discovery stage, without the need to validate the hits with a secondary assay. For example, shown in Figure 5 is the FAC-MS chromatogram resulting from a mixture of 4 compounds, the void marker M3 (line a), norethindrone (line b), and 2 compounds that we had previously identified as binding to hERβ, OM89432 (line c) and OM90295 (not monitored). In this case, increasing breakthrough times and 2 rollups are evident. First, norethindrone with a K d = 1.6 µM generated a breakthrough time of 18 min and is rolled up by a stronger ligand, OM89432 (FAC-MS-measured K d = 0.75 µM), which generated a breakthrough time of 47 min. Second, OM89432 is then in turn rolled up by an even stronger ligand, OM90295 (FAC-MS-measured K d = 0.1 nM), but was not monitored by FAC-MS. These results exemplify the preliminary binding SAR information obtainable from either the breakthrough times and/or the combination of observing rollups. Moreover, whenever a rollup is observed, it indicates that there is at least 1 ligand in the mixture that is responsible and possesses a K d that is stronger than the ligand that is rolled up. It is also worth noting that although OM90295 was not monitored by FAC-MS, the ability to see the effect of this ligand without actually monitoring it is a salient feature of FAC-MS. Obviously, with this hERβ system, both FAC-MS screening methods are possible. Although norethindrone is ideally suited as an indicator as shown above-in fact, we have used this immobilized hERβ and screened a small library of compounds looking for shifts of the norethindrone front as part of a discovery program-we will not be presenting that data here.
Instead, to detail FAC-MS automation as well as the value of the Q1 scan method, we mixed 100 unique compounds together and infused the mixture through the hERβ column and, using the MS in its full scan mode, scanned an entire m/z range from 100 to 1200. The genesis of these compounds stemmed from a virtual screening paradigm similar to the computational paradigm we used for a kinase target, 13 where compounds were purchased from commercial vendor databases that were predicted to bind to the ligand binding domain of hERβ. Because the molecular weight for each of the 100 compounds was known, using proprietary software, the individual breakthrough fronts were identified as shown in Figure 6A . For this case, the concentration of the individual compounds was set to 1 µM to ensure that the final DMSO concentration was kept to a minimum of 2% v/v. We have also shown that we can put 200 compounds in mixtures (each compound at 0.5 µM) and successfully carry out a Q1 scan (data not shown). For the case of the 100-compound mixture in Figure 6A , compounds with the longest breakthrough times are the most interesting, and so for this case, it would be the group with the longest breakthrough fronts compared to the void marker.
Picking out the breakthrough front times for the complicated FAC-MS chromatogram of Figure 6A manually would be a tedious process. Because, however, what is important is the inflection point (or the point where the first derivative is 0) for each m/z versus time for each compound, proprietary software was written that calculates this automatically; this inflection point is represented by the bar diagram as shown in Figure 6B . These bar lines represent the time when the first derivative is 0 for each m/z value of the breakthrough fronts of Figure 6A . Because compounds may also possess binding to the FAC-MS system (capillary lines, columns, beads, etc.), the nonspecific binding of the compound mixtures is also determined using columns containing beads that do not contain any immobilized protein. The net binding times (t I -t 0 -t nsb ) for this 100-compound mixture (actually only 99, as 1 compound was not detected by MS) are shown in Table 1 . Very readily, it can be seen that the compounds with the greatest net binding times would be of greatest interest. For example, in this case, 16 of 99 compounds have net binding times greater than 5 min (marked with an asterisk in Table 1 ). Because norethindrone (K d = 1.6 µM) gave a net binding time of 0.67 min in this mixture, this indicates that these ligands probably possess submicromolar binding affinities unless, of course, they are binding at an allosteric site. This high hit rate is perhaps not surprising because we employed a rather vigorous docking and scoring virtual screening paradigm.
FAC-MS runtimes will vary for each immobilized target and depend on a number of conditions such as column length, immobilized protein density, and ligand concentration. As shown in Figure 6A , the total runtime was ~30 min, and because 2 columns can be used whereby one is being regenerated with buffer while the other is being used, we are extrapolating that in a continuous 24-h operation with 200 ligands/mixture, the number of ligands that can be screened could approach 10,000, suggesting that FAC-MS should be considered as a moderatethroughput binding assay.
As with any screening assay, a number of potential issues could arise during an automated FAC-MS screening run of a large number of ligands that need to be discussed: (1) Because detection is by MS, the compounds must ionize to be "seen." The MS conditions were optimized in order for the majority of the compounds to form the M+H ions. In this case, one of the ligands (OM89395) did not ionize, and in general, we have noted that upwards of 10% of ligands do not ionize with initial MS settings. Because, however, the molecular weights of all the ligands in the mixture will be known, any ligands that do not ionize will be flagged. (2) The kinetics of binding (i.e., fast or slow on-or offrates) can affect the shape of the breakthrough front curves (e.g., slow on-rates typically result in slowly rising breakthrough fronts; see Fig. 6A ) and can potentially affect the binding of other ligands by causing delayed breakthrough times. (3) If there is a ligand in a mixture that turns out to either covalently bind to the immobilized target or to be a very tight binder (<~100 nM), then this could affect screening by essentially rendering the column inactive. Because, however, the columns are being reused, this "dead" column would clearly be identified during the next run.
Most early hit screening assays require the use of single compounds at an expected purity of about 95%. In contrast to this, with FAC-MS, we have taken compounds at their 95% pure level and mixed them with other compounds so that they are now at < 1% pure level (in the case of 100 compounds) and determined their binding affinity as well as their rank order. This has important considerations for medicinal chemistry programs in drug discovery.
First, for the compounds to be made, very little material is needed (0.1-1 mg), nor is a high degree of purity required. As such, there is no need to optimize the exploratory reactions of the early synthetic chemistry to test compound binding hypotheses. There will, however, be a concentration limit of the ligands in order to be seen by the mass spectrometer. Although it is not possible to say what this limit is because ionization varies with each ligand, we could still see the ligands in the 200-compound mixture, and these were not more than 0.5% pure.
Second, because at the early drug discovery stage, the objective is to find and generate confidence that the hits identified will prove useful in further downstream optimization stages, FAC-MS, with its ability to evaluate multiple ligands simultaneously, offers the real possibility to generate preliminary binding SAR information very early on. As shown in Figure 5 , data are generated (albeit with only 4 compounds) where the breakthrough fronts (and associated rollups) can be accounted for based on the affinity of the ligands. Similarly, in the larger primary screening run shown in Figure 6A , because the structures of the compounds can be readily linked to the net binding data of Table 1 , it would be possible to deduce preliminary SAR binding observations. Moreover, up to about 5 min, there are a variety of rollups observed for multiple compound traces, including a rollup of norethindrone (K d = 1.6 µM), which indicates that in this mixture of 100 compounds, at least 1 compound present has a binding affinity for hERβ that is stronger than 1.6 µM. There are also a number of traces in this region that are not rolled up, but, as shown in Table 1 , there are numerous t I -t 0 -t nsb values close to 0, indicating that these ligands are inactive or very weakly binding with similar nonspecific breakthrough binding times in the absence of hERβ.
Recently, it has been reported that a 2-stage AS-MS system comprising a size exclusion chromatography (SEC) separation of the protein-ligand complex from unbound ligands, followed by a reverse-phase chromatography (RPC)-MS step, where the bound ligands are dissociated from the protein, can generate ranking data and binding site classification. 15 The value of this methodology is certainly evident and, as with FAC-MS, has the ability to generate preliminary SAR information. It should be noted that one advantage with FAC-MS is that with multiple ligand screening, if there were a ligand that could not be seen by MS, this ligand would be flagged for further analysis, such as OM90295, mentioned in Figure 5 .
It has also been reported that the insertion of liquid chromatography (LC) preparation step into FAC-MS improves screening rates and compound library coverage. 16 Although the LC fractionation step may improve sensitivity and eliminate the need for FAC-MS-friendly buffers, it clearly complicates Table 1 
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Results for a 100-Ligand Mixture Screened with Immobilized hERβ the process. Any advantages over conventional FAC-MS are not evident because ligands cannot be ranked as accurately, the process involves the added time and inconvenience for the evaporation/reconstitution step, and, as stated, only 5000 ligands can be screened per day per instrument. In summary, using automated FAC-MS incorporating data management, we are extrapolating that on the order of 10,000 ligands could be screened per day, and this very importantly includes compound ranking. Certainly, FAC-MS-friendly buffers are needed, but to date, most of the common buffers can be used, with the exception of the "Tris buffer." In addition, if there are cases where multiple ligand mixtures result in precipitation as a result of a high total library component concentration, the automatic data management system will flag this mixture for further analysis. With this moderate FAC-MS throughput now established, preliminary SAR binding information (typically not seen in early primary hit discovery HTS assays) could be obtained, whether screening diverse or closely related focused libraries, by observing the rank order of the library members in the various mixtures.
